体内表观遗传CRISPR筛选鉴定Asf1a为Kras突变肺腺癌免疫治疗靶点
在Kras G12D/Trp53-/-肺腺癌模型中,通过体内表观遗传CRISPR筛选发现组蛋白伴侣Asf1a缺失可使肿瘤对抗PD-1治疗敏感。机制上,肿瘤细胞内在Asf1a缺陷通过上调GM-CSF诱导免疫原性巨噬细胞分化,并联合抗PD-1增强T细胞活化。结果为ASF1A抑制联合抗PD-1免疫治疗提供了新策略。
要点
- Asf1a缺失使Kras突变肺腺癌对抗PD-1治疗敏感。
- Asf1a缺陷通过上调GM-CSF诱导M1样巨噬细胞极化。
- ASF1A抑制联合抗PD-1可作为潜在新策略。
核心结论
- Asf1a是Kras突变肺腺癌对抗PD-1治疗敏感性的关键调节因子。
- ASF1A抑制联合抗PD-1免疫治疗为Kras突变肺腺癌提供新策略。
研究设计与样本
- 构建表观遗传聚焦的单向导RNA文库,在Kras G12D/Trp53-/-肺腺癌模型中进行体内CRISPR筛选。
主要发现
- 肿瘤细胞Asf1a缺失使Kras G12D/Trp53-/-肺腺癌模型对抗PD-1治疗敏感。
- 肿瘤细胞内在Asf1a缺陷通过上调GM-CSF诱导肿瘤微环境中免疫原性巨噬细胞分化。
- Asf1a缺陷联合抗PD-1增强T细胞活化。
临床怎么用
- ASF1A抑制联合抗PD-1可能作为Kras突变肺腺癌的候选联合免疫治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite substantial progress in lung cancer immunotherapy, the overall response rate in patients with KRAS-mutant lung adenocarcinoma (LUAD) remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune responses-such as epigenetic modulation of antitumor immunity-is therefore an attractive strategy. To identify epigenetic regulators of tumor immunity, we constructed an epigenetic-focused single guide RNA library and performed an in vivo CRISPR screen in a Kras G12D/Trp53 -/- LUAD model. Our data showed that loss of the histone chaperone Asf1a in tumor cells sensitizes tumors to anti-PD-1 treatment. Mechanistic studies revealed that tumor cell-intrinsic Asf1a deficiency induced immunogenic macrophage differentiation in the tumor microenvironment by upregulating GM-CSF expression and potentiated T-cell activation in combination with anti-PD-1. Our results provide a rationale for a novel combination therapy consisting of ASF1A inhibition and anti-PD-1 immunotherapy. SIGNIFICANCE: Using an in vivo epigenetic CRISPR screen, we identified Asf1a as a critical regulator of LUAD sensitivity to anti-PD-1 therapy. Asf1a deficiency synergized with anti-PD-1 immunotherapy by promoting M1-like macrophage polarization and T-cell activation. Thus, we provide a new immunotherapeutic strategy for this subtype of patients with LUAD.See related commentary by Menzel and Black, p. 179.This article is highlighted in the In This Issue feature, p. 161.
引用
- Li F, Huang Q, Luster TA, et al. In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma. Cancer Discov. 2019. PMID: 31744829. doi:10.1158/2159-8290.CD-19-0780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。